Thyroid cancer pathology: Insights from a developing region
DOI:
https://doi.org/10.7196/SAMJ.2025.v115i9.2997Keywords:
thyroid cancer, healthcare, south africa, thyroid, oncology, pathological typesAbstract
Background. The South African (SA) health sector and laboratories comprise a dual system that includes public and private providers. SA studies illustrate diverse thyroid cancer incidence across provinces, with papillary thyroid cancer (PTC) more prevalent in urban provinces than follicular thyroid cancer (FTC) and anaplastic thyroid carcinoma.
Objectives. To provide a deeper insight into the geographic intricacies of thyroid cancer types from public and private provider perspectives.
Methods. This study investigated thyroid cancer pathology in SA between 2015 and 2019, overall and by province and facility type (private, public). Laboratories provided data in different formats, requiring manual processing. The data extracted included date of birth, sex, province, specimen type and final histology results.
Results. A total of 14 157 reports were included, of which 3 235 were thyroid cancers. Multiple challenges were experienced in terms of data processing. The public sector contributed 53.6% of thyroid cancer cases. Preoperative cytology was performed in 19.8% of thyroid cancers, and was diagnostic in 23.6%. There was significantly more FTC in the public sector (20.8% v. 5.6%), and more PTC in the private sector (87.1% v. 55.2%). T3 tumours were most prevalent in the public sector (52.3%), and T1 tumours in the private (38.8%).
Conclusion. The dual SA health system and the geographical distribution of the population appear to influence the pathological landscape of thyroid cancer. Standardised thyroid cancer reporting across all public and private laboratories in the form of a prospective national thyroid registry would allow for a more accurate evaluation of thyroid disease, ultimately improving thyroid cancer care in SA.
References
1. Statistics South Africa. Total population of South Africa in 2023, by province. Stats SA, 2023. https:// www.statista.com/statistics/1112169/total-population-of-south-africa-by-province/ (accessed 28 May 2023).
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
3. World Health Organization. WHO Report on Cancer: Setting Priorities, Investing Wisely and Providing Care for All. Geneva: WHO, 2020. https://www.who.int/publications-detail/who-report- on-cancer-setting-priorities-investing-wisely-and-providing-care-for-all (accessed 21 August 2025).
4. Deng Y, Li H, Wang M, et al. Global burden of thyroid cancer from 1990 to 2017. JAMA Network Open 2020;3(6):1-14. https://doi.org/10.1001/jamanetworkopen.2020.8759
5. Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: A population-based study. Lancet Diab Endocrinol 2021;9(4):225-234. https://doi. org/10.1016/S2213-8587(21)00027-9
6. Wiltshire JJ, Drake TM, Uttley L, Balasubramanian SP. Systematic review of trends in the incidence rates of thyroid cancer. Thyroid 2016;26(11):1541-1552. https://doi.org/10.1089/thy.2016.0100
7. Bai Y, Kakudo K, Jung CK. Updates in the pathologic classification of thyroid neoplasms: A review of the World Health Organization classification. Endocrinol Metabol 2020;35(4):696-715. https://doi. org/10.3803/ENM.2020.807
8. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26(1):1-133. https://doi.org/10.1089/thy.2015.0020
9. Asimakopoulos P, Nixon IJ, Shaha AR. Differentiated and medullary thyroid cancer: Surgical management of cervical lymph nodes. Clin Oncol 2017;29(5):283-289. https://doi.org/10.1016/j. clon.2017.01.001
10. Barletta JA, Nosé V, Sadow PM. Genomics and epigenomics of medullary thyroid carcinoma: From sporadic disease to familial manifestations. Endocrine Pathol 2021;32(1):35-43. https://doi. org/10.1007/s12022-021-09664-3
11. Hu J, Zhao N, Kong R, Wang D, Sun B, Wu L. Total thyroidectomy as primary surgical management for thyroid disease: Surgical therapy experience from 5 559 thyroidectomies in a less-developed region. World J Surg Oncol 2016;14(1):1-7. https://doi.org/10.1186/s12957-016-0772-1
12. Marti JL, Morris LGT, Ho AS. Selective use of radioactive iodine (RAI) in thyroid cancer: No longer ‘one size fits all’. Euro J Surg Oncol 2018;44(3):348-356. https://doi.org/10.1016/j.ejso.2017.04.002
13. Araque KA, Gubbi S, Klubo-Gwiezdzinska J. Updates on the management of thyroid cancer. Hormone
Metabolic Res 2020;52(8):562-577. https://doi.org/10.1055/a-1089-7870
14. Coca-Pelaz A, Shah JP, Hernandez-Prera JC, et al. Papillary thyroid cancer – aggressive variants and
impact on management: A narrative review. Adv Ther 2020;37(7):3112-3128. https://doi.org/10.1007/
s12325-020-01391-1
15. Grigsby PW, Michalski JM, Doherty GM. Childhood and adolescent thyroid carcinoma. Cancer 2002;95(4):724-729. https://doi.org/10.1002/cncr.10725
16. Guerrero MA, Clark OH. Controversies in the management of papillary thyroid cancer revisited. ISRN Oncol 2011;2011(1):1-5. https://doi.org/10.5402/2011/303128
17. Bombil I, Bentley A, Kruger D, Luvhengo TE. Incidental cancer in multinodular goitre post thyroidectomy. S Afr J Surg 2014;52(1):5-9. https://doi.org/ 10.7196/SAJS.1970
18. Kalk WJ, Sitas F, Patterson AC. Thyroid cancer in South Africa – an indicator of regional iodine deficiency. S Afr Med J 1997;87(6):735-738.
19. Robertson B, Parker M, Shepherd L, et al. Nodal disease predicts recurrence whereas other traditional factors affect survival in a cohort of South African patients with differentiated thyroid carcinoma. Canc Head Neck 2018;3(1):1-8. https://doi.org/10.1186/s41199-018-0037-5
20. Mulaudzi TV, Ramdial PK, Madiba TE, Callaghan RA. Thyroid carcinoma at King Edward VIII Hospital, Durban, South Africa. East Afr Med J 2001;78(5):242-245. http://doi.org/10.4314/eamj. v78i5.9046
21. Conradie W, Luvhengo T, Lübbe JA, et al. The clinicopathological landscape of thyroid cancer in South Africa – a multi-institutional review. World J Surg 2024;48(12)2863-70. https://doi.org/10.1002/ wjs.12353
22. Hong S, Xie Y, Cheng Z, et al. Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability. Oncogene 2022;41(47):5121-5132. https://doi.org/10.1038/ s41388-022-02499-0
23. Song YS, Park YJ. Genomic characterisation of differentiated thyroid carcinoma. Endocrinol Metabol 2019;34(1):1-10. https://doi.org/10.3803/EnM.2019.34.1.1
24. Rossi ED, Pantanowitz L, Hornick JL. A worldwide journey of thyroid cancer incidence centred on tumour histology. Lancet Diabetes Endocrinol 2021;9(4):193-194. https://doi.org/10.1016/S2213- 8587(21)00049-8
25. Cairncross L, Panieri E. Pre-operative diagnosis of thyroid cancer: Clinical, radiological and pathological correlation. S Afr J Surg 2013;51(2):46-49. https://doi.org/10.7196/SAJS.1261
26. Chagi N, Bombil I, Mannell A. The profile of thyroid cancer in patients undergoing thyroidectomy at Chris Hani Baragwanath Academic Hospital. S Afr J Surg 2019;57(3):55. https://doi.org/10.17159/2078- 5151/2019/v57n3a2928
27. Boyraz B, Sadow PM, Asa SL, Dias-Santagata D, Nosé V, Mete O. Cribriform-morular thyroid carcinoma is a distinct thyroid malignancy of uncertain cytogenesis. Endocr Pathol 2021;32(3):327- 335. https://doi.org/10.1007/s12022-021-09683-0
28. Department of Water and Sanitation, South Africa. Rural population percentages by province (April 2025 estimates). DWS Data Portal: Demography – Population Rural/Urban. Pretoria: DWS, 2025. https://ws.dws.gov.za/wsks/DefaultList.aspx?DataTopicDetailID=92&DataTopicID=1&DisplayTypeI d=1&LvlID=10&PerspectiveID=0&SubjectAreaID=1&utm_] (accessed 21 August 2025).
29. Ghossein R, Barletta JA, Bullock M, et al. Data set for reporting carcinoma of the thyroid: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Hum Pathol 2021;110:62-72. https://doi.org/10.1016/j.humpath.2020.08.009
30. Alseddeeqi E, Altinoz A, Oulhaj A, Suliman A, Ahmed LA. Incidence of thyroid cancer in Abu Dhabi, UAE: A registry-based study. J Canc Res Therapeut 2023;19(2):321. https://doi.org/10.4103/jcrt. jcrt_999_21
31. Hussain F, Iqbal S, Mehmood A, Bazarbashi S, ElHassan T, Chaudhri N. Incidence of thyroid cancer in the Kingdom of Saudi Arabia, 2000 - 2010. Hematol/Oncol Stem Cell Ther 2013;6(2):58-64. https:// doi.org/10.1016/j.hemonc.2013.05.004
32. Jayarajah U, Fernando A, Prabashani S, Fernando EA, Seneviratne SA. Incidence and histological patterns of thyroid cancer in Sri Lanka 2001 - 2010: An analysis of national cancer registry data. BMC Cancer 2018;18(1):163. https://doi.org/10.1186/s12885-018-4083-5
33. Boukheris H, Bettayeb A, Anderson LA, et al. Changes in the demographic and clinicopathological characteristics of thyroid cancer: A population-based investigation in Algeria, 1993-2013. J Cancer Epidemiol 2020;2020:7812791. https://doi.org/10.1155/2020/7812791
34. Surveillance, Epidemiology and End Results Program. SEER Cancer Statistics Review, 1975-2018. https://seer.cancer.gov/csr/1975_2018/index.html (accessed 24 June 2024).
35. Long K. Building foundations: Invited commentary: The clinicopathological landscape of thyroid cancer in South Africa: A multi-institutional review. World J Surg 2024;48(12):2871-2872. https://doi. org/10.1002/wjs.12392
Downloads
Published
Issue
Section
License
Copyright (c) 2025 W Conradie; J Lübbe; L Martin, T Luvhengo, R Razack, A Afrogheh, F Crabbia, S Nayler, J Davies, K Baatjes
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
